Barclays
SPRO icon

Barclays’s Spero Therapeutics SPRO Stock Holding History

Barclays’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7 Buy
+6
New +$8 ﹤0.01% 5212
2022
Q3 		– Sell
-204
Closed – – 5118
2022
Q2 		$0 Sell
204
-3,726
-95% -$10.8K ﹤0.01% 5246
2022
Q1 		$35K Sell
3,930
-25,441
-87% -$261K ﹤0.01% 4249
2021
Q4 		$470K Buy
29,371
+19,406
+195% +$308K ﹤0.01% 3233
2021
Q3 		$183K Buy
9,965
+4,401
+79% +$70.6K ﹤0.01% 3665
2021
Q2 		$77K Sell
5,564
-16,076
-74% -$225K ﹤0.01% 3947
2021
Q1 		$319K Buy
21,640
+14,940
+223% +$263K ﹤0.01% 3467
2020
Q4 		$130K Sell
6,700
-1,858
-22% -$29K ﹤0.01% 4008
2020
Q3 		$96K Sell
8,558
-1,151
-12% -$13.6K ﹤0.01% 4278
2020
Q2 		$130K Buy
9,709
+5,389
+125% +$60.5K ﹤0.01% 4355
2020
Q1 		$34K Sell
4,320
-7,041
-62% -$62.1K ﹤0.01% 5433
2019
Q4 		$109K Buy
11,361
+5,853
+106% +$63.1K ﹤0.01% 5439
2019
Q3 		$58K Sell
5,508
-1,281
-19% -$13.5K ﹤0.01% 5835
2019
Q2 		$78K Buy
6,789
+4,222
+164% +$50.8K ﹤0.01% 5863
2019
Q1 		$33K Buy
2,567
+2,131
+489% +$22.6K ﹤0.01% 6133
2018
Q4 		$2K Sell
436
-3,121
-88% -$25.3K ﹤0.01% 6738
2018
Q3 		$37K Buy
3,557
+3,069
+629% +$35.6K ﹤0.01% 6234
2018
Q2 		$7K Sell
488
-803
-62% -$10.3K ﹤0.01% 6645
2018
Q1 		$19K Buy
1,291
+335
+35% +$4.06K ﹤0.01% 6454
2017
Q4 		$11K Buy
+956
New +$11.7K ﹤0.01% 6496

Other funds holding SPRO

GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
StoneX Group
StoneX Group New York $2.75B AUM 24.25% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Capital Asset Advisory Services
Capital Asset Advisory Services Williamston, Michigan $2.94B AUM 11.83% 1-Year Est. Return
Three Seasons Wealth
Three Seasons Wealth Salt Lake City, Utah $1.12B AUM 34.1% 1-Year Est. Return
Oppenheimer & Co
Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return
Ritholtz Wealth Management
Ritholtz Wealth Management New York $6.96B AUM 24% 1-Year Est. Return

Barclays's SPRO Position: Q3 2026 in Review

Barclays opened a new position in Spero Therapeutics (SPRO) in Q3 2026: 6 shares worth $7. The stake represents ﹤0.01% of the portfolio and ranks #5212 among its holdings. This is a return to the name: Barclays previously reported a position in SPRO as recently as Q2 2022.

Barclays first reported a position in SPRO in Q4 2017 and has held it in 20 quarters since. The position peaked at $470K in Q4 2021. 17 funds tracked by Wall St. Rank hold SPRO as of Q3 2026.

  • Barclays held 6 shares of Spero Therapeutics worth $7 as of Q3 2026.
  • Spero Therapeutics was a new Barclays position in Q3 2026.
  • Spero Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #5212 holding.
  • Barclays first reported a position in Spero Therapeutics in Q4 2017 and has held it in 20 quarters since.
  • Barclays's Spero Therapeutics position peaked at $470K in Q4 2021.
  • 17 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.